However, the global inhibition of deglycation has yet to be extensively reported in all other cancer types with selectivity and tissue specificity to develop novel FN3K inhibitors to maintain Nrf2 in a glycated state or to modulate the role of Nrf2 activity in cancers. The gene discussed is FN3K; the disease is cancer.